Pharmafile Logo
Pharmafocus logo
Advanced Search
novartis_side_building

Novartis expands Pear partnership to tackle opioid and substance use disorder

April 23, 2018
Research and Development, Sales and Marketing Novartis, Pear Therapeutics, Sandoz, opioids, pharma, substance use disorder

Novartis has announced that it will expand its current partnership with Pear Therapeutics, signed in March, as it reveals that …

News
biogen_idec_hillerod_2008

Biogen boosts pipeline with $1bn Ionis deal

April 23, 2018
Sales and Marketing Biogen, Ionis, Spinraza, biotech, drugs, pharma, pharmaceutical

Somewhat unusually for an early drug development deal, Biogen has put down a serious amount of cash up-front in its …

News
credit_-_daniel_leal-olivas-afp

CHMP rejects AB Science’s ALS therapy in Europe

April 23, 2018
Sales and Marketing AB Sciences, EMA, European Medicines Agency, ab science, als, masitinib, pharma

AB Science has revealed that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a …

News
frs-logo_0

Fresenius attempts to back out of $4.75bn deal for Akorn

April 23, 2018
Sales and Marketing

Fresenius has announced its intention to terminate the merger agreement with Akorn, over the $4.75 billion deal that the two …

News
houses-of-parliament-1055056_960_720

UK Ministers call on Vertex to speed up price negotiations

April 23, 2018
Sales and Marketing NHS, NICE, Orkambi, UK government, Vertex, biotech, drugs, pharma, pharmaceutical

After a parliamentary debate in the House of Commons regarding making Orkambi available to patients with cystic fibrosis (CF), MPs …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

April 20, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, EMA, GW Pharma, J&J, JJ, MHRA, Mylan, Novartis, Sanofi, Shire, Takeda, biotech, drugs, epipen, keytruda, pharma, pharmaceutical

It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …

News

Lilly and Incyte’s resubmission of arthritis drug data fails to assuage FDA concerns

April 20, 2018
Medical Communications, Sales and Marketing Eli Lilly, FDA, Incyte, baricitinib, pharma, rheumatoid arthritis

Eli Lilly and Incyte are facing more complications in the US approval of their experimental rheumatoid arthritis (RA) drug baricitinib …

News

Prototype skin implant signals cancer by forming a visible mole

April 20, 2018
Medical Communications Cancer, device, implant, medtech, pharma

Researchers working with Professor Martin Fussenegger at the Department of Biosystems Science and Engineering at ETH Zurich in Basel have …

News
gw_pharma

FDA advisory committee sets GW Pharma up for approval

April 20, 2018
Medical Communications, Sales and Marketing Epidiolex, GW Pharma, biotech, drugs, pharma, pharmaceutical

After the FDA advisory committee unanimously recommended GW Pharma’s Epidiolex for approval, the chances of it not receiving the nod …

News

Allergan out but Takeda sticks to guns on Shire

April 20, 2018
Medical Communications, Sales and Marketing Allergan, Shire, Takeda, biotech, drugs, pharma, pharmaceutical

Allergan performed an odd about-turn after initially declaring its interest in pursuing a deal for Shire, before reneging on that …

News
shutterstock_244903099

The UK’s Royalties withholding tax consultation: Pushing extraterritorial boundaries

April 19, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Norton Rose Fulbright, feature, pharma, tax consultation

Norton Rose Fulbright’s Dominic Stuttaford, James Baillieu and Susie Brain discuss the implications regarding the recent reforms to cross-border royalties.The …

Feature
astrazeneca_building_white

AZ’s Tagrisso gets FDA nod in first-line EGFR-mutated lung cancer

April 19, 2018
Sales and Marketing AstraZeneca, Cancer, EGFR-TKIs, NSCLC, Tagrisso, lung cancer, pharma

AstraZeneca has announced that its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) has received approval from …

News
8384110298_da510e0347_c

BenevolentAI financing round takes valuation to $2bn+

April 19, 2018
Medical Communications BenevolentAI, biotech, drugs, pharma, pharmaceutical

BenevolentAI, a London based drug discovery biotech, has revealed that a $115 million financing round now sees the company valued …

News
john_tsai

Novartis snatches Amgen and BMS veteran for CMO and Drug Development Head

April 19, 2018
Medical Communications Amgen, BMS, Bristol-Myers Squibb, Novartis, appointment, pharma

Dr John Tsai has been welcomed to the fold as Novartis’ new Head of Global Development and Chief Medical Officer, …

News
merck_kgaa_pyramid_use_with_credit

Merck KGaA finds consumer health buyer in P&G for €3.4bn

April 19, 2018
Sales and Marketing Merck KGaA, P&G, Pfizer, biotech, drugs, pharma, pharmaceutical

Merck KGaA has successfully found a buyer for its healthcare unit, after Proctor & Gamble announced that it was prepared …

News
brexit_flag_0

EMA initiates divorce process from the UK’s MHRA

April 19, 2018
Medical Communications EMA, UK government, biotech, brexit, drugs, pharma, pharmaceutical

The first stage of separation for the EMA from the UK came with the decision to relocate its headquarters to …

News
iannone

Immunomedics’ whirlwind in the C-suite continues

April 18, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Immunomedics hasn’t had the most straight forward year, its $2 billion deal with Seattle Genetics was scuppered by activist investors, …

Appointment
bill_chin_headshot

Frequency Therapeutics hires industry vet

April 18, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Frequency Therapeutics is a biotech with big ideas and it has made a big appointment to back up those ideas, …

Appointment

BMS’ Opdivo+Yervoy combo secures FDA approval in kidney cancer

April 18, 2018
Research and Development, Sales and Marketing BMS, Bristol Myers Swuibb, Cancer, FDA, Yervoy, carcinoma, opdivo, pharma

The FDA has announced its approval of a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), both products from Bristol Myers …

News
epi-pen_1_3

EpiPen shortage hits UK and Canada hard, but not US

April 18, 2018
Research and Development, Sales and Marketing Mylan, Pfizer, biotech, drugs, epipen, pharma, pharmaceutical

Manufacturing issues at the single Pfizer plant that produces the EpiPen epinephrine injector has caused serious shortages in the UK …

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026